US Patent Office Issues New Patent to PUR Biologics for Advanced Cartilage Regeneration and Arthritis Solutions
IRVINE, CA / ACCESSWIRE / August 14, 2023 / PUR Biologics, a wholly owned subsidiary of HippoFi (OTCPK:ORHB), proudly announces its newly granted patent, marking a significant advancement in addressing the debilitating effects of osteoarthritis and cartilage degeneration. This addition to the Company’s intellectual property portfolio provides PUR Biologics exclusive rights to innovative methods and compositions that utilize induced Pluripotent Stem Cells (iPSCs) to produce an advanced extracellular matrix (ECM…
Read More
0
